Kadimastem Ltd. news
NESS ZIONA, ISRAEL, March 9, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis (ALS).
Specifically, the patent allows for t
Ness Ziona, Science Park, May 18, 2022 - Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS).
As part of this initiative, the company has signed a service agreement with Hadasit
NESS ZIONA, ISRAEL, March 3, 2022 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant from the Israel Innovation Authority (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million).
The funds will be used to advance the filing of an IND with the FDA by the end of 2022, to secure the approval of the FDA of the anticipated Phase
NESS ZIONA, ISRAEL, December 12, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant of NIS 1.6 million ($500K), 40% of the approved budget of NIS 4 million ($1.29M) from the Israel Innovation Authority (IIA).This brings the total amount of financing raised by Kadimastem in 2021 to NIS 51.6 milli
NESS ZIONA, ISRAEL, November 29, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a cure for diabetes, announces a raise of 10 million NIS ($3.2 million) from ILEX Medical (TASE: ILX) one of the largest healthcare companies in Israel, in a private financing round. The raise was completed at a price of 4.26 NIS ($1.35) per share (about 5% higher than the closing price of the share on the eve of the board of directors meeting).